Fenwick Represents Jupiter Endovascular in $40M Series B Funding

Fenwick represented Jupiter Endovascular, a medical technology startup, in its $40 million Series B funding. The round was led by Sonder Capital with participation from Senvest Management, LB Investment, and a new strategic corporate investor.

Jupiter Endovascular will use the funds to complete its ongoing SPIRARE II pivotal clinical trial, prepare for commercialization, and develop new clinical applications for its TFX platform technology. Additional information can be obtained here.

The Fenwick transaction team was led by corporate partner Matt Rossiter and included associates James Li, Seena Razavi, and Jack Zukin.